Orphan drugs: Regulation is flawed

Carl E Counsell

doi:10.1136/bmj.c7016

Orphan drugs: Regulation is flawed

Research output: Contribution to journal › Letter › peer-review

Original language	English
Article number	c7016
Journal	BMJ (Clinical research ed.)
Volume	341
DOIs	https://doi.org/10.1136/bmj.c7016
Publication status	Published - 7 Dec 2010

Keywords

4-aminopyridine
drug approval
humans
orphan drug production
potassium channel blockers
quality control
randomized controlled trials as topic

Access to Document

10.1136/bmj.c7016

Cite this

@article{38b322e6e6a04787a637bf82bbae4571,

title = "Orphan drugs: Regulation is flawed",

keywords = "4-aminopyridine, drug approval, humans, orphan drug production, potassium channel blockers, quality control, randomized controlled trials as topic ",

author = "Counsell, {Carl E}",

year = "2010",

month = dec,

day = "7",

doi = "10.1136/bmj.c7016",

language = "English",

volume = "341",

journal = "BMJ (Clinical research ed.)",

issn = "1468-5833",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Orphan drugs

T2 - Regulation is flawed

AU - Counsell, Carl E

PY - 2010/12/7

Y1 - 2010/12/7

KW - 4-aminopyridine

KW - drug approval

KW - humans

KW - orphan drug production

KW - potassium channel blockers

KW - quality control

KW - randomized controlled trials as topic

U2 - 10.1136/bmj.c7016

DO - 10.1136/bmj.c7016

M3 - Letter

C2 - 21139004

SN - 1468-5833

VL - 341

JO - BMJ (Clinical research ed.)

JF - BMJ (Clinical research ed.)

M1 - c7016

ER -